This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...